Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models

Journal of Nuclear Medicine

Volumn 46, Issue 3, 2005, Pages 495-501

  Van Schaijk, Frank G ^a   Oosterwijk, Egbert ^a   Molkenboer Kuenen, Janneke D ^a   Soede, Annemieke C ^a   McBride, Bill J ^b   Goldenberg, David M ^b   Oyen, Wim J G ^a   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IMMUNOMEDICS INC   (United States)

Author keywords

Bispecific antibody G250xDTIn 1; G250 antigen; Pretargeting strategy; Renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; INDIUM 111; IODINE 125; MONOCLONAL ANTIBODY G250; PENTETIC ACID; 111IN DIDTPA FKYK; 111IN-DIDTPA-FKYK; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; DRUG DELIVERY SYSTEM; KIDNEY TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; KIDNEY NEOPLASMS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; OLIGOPEPTIDES; ORGAN SPECIFICITY; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 17844395217     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Goldenberg DM. Tumor imaging with monoclonal antibodies. J Nucl Med. 1983;24:360-362.
2. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38:858-870.
3. Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM, Corstens FH. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med. 2001;28:1725-1735.
4. Goodwin DA, Mears CF, McTigue M, David GS. Monoclonal antibody hapten radiopharmaceutical delivery. Nucl Med Commun. 1986;7:569-580.
5. Kranenborg MH, Boerman OC, Oosterwijk-Wakka JC, De Weijert MC, Corstens FH, Oosterwijk E. Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res. 1995;50(suppl):5864s-5867s.
6. Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.
7. 188Re- labeled bivalent hapten: biodistribution and dosimetry studies. J Nucl Med. 2001;42:146-153.
8. 188Re-labeled peptide. Bioconjug Chem. 2000;11:842-854.
9. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 1990;50:3445-3452.
10. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res. 2003;9(suppl):3897s-3913s.
11. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. Establishment and characterization of human renal cell cancer and normal kidney cell lines. Cancer Res. 1990;50:5531-5536.
12. Beniers AJ, Peelen WP, Schaafsma, et al. Establishment and characterization of five new human renal tumor xenografts. Am J Pathol. 1992;140:483-495.
13. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489-494.
14. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741-746.
15. 188Re. Clin Cancer Res. 2003;9(suppl):3880s-3885s.
16. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221-4226.
17. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
18. Van Oosterhout YV, Van den Herik-Oudijk IE, Wessels HM, De Witte T, Van de Winkel JG, Preijers FW. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res. 1994;54:3527-3532.
19. Westphal JR, Van't Hullenaar RG, Van der Laak JA, et al. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer. 1997;76:561-570.
20. Blumenthal RD, Sharkey RM, Kashi R, Sides K, Stein R, Goldenberg DM. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts. Tumour Biol. 1997;18:367-377.
21. Sands H, Shah SA, Gallagher BM. Vascular volume and permeability of human and murine tumors grown in athymic mice. Cancer Lett. 1985;27:15-21.
22. Bander NH. Comparison of antigen expression of human renal cancers in vivo and in vitro. Cancer. 1984;53:1235-1239.
23. Baxter LT, Yuan F, Jain RK. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res. 1992;52:5838-5844.
24. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50(suppl):814s-819s.